(ShareCast News) - Inhaled airways disease focused business Vectura Group raised expectations for 2016 as it said it is making progress with the June Skyepharma merger. The company raised revenue expectations for the nine month period ended 31 December, due to strong growth from its partnered market
Read more(ShareCast News) - Inhaled airways disease focused pharmaceuticals company Vectura Group confirmed an announcement from its alliance partner Novartis on Monday, that new analyses from the head-to-head FLAME study confirmed that Ultibro Breezhaler is a "more effective option" for patients at risk of
Read more(ShareCast News) - Novartis has published data about a respiratory drug combination delivered using an inhaler designed in collaboration with Vectura that shows patients are twice as likely to persist with treatment over 12 months than with a popular product already on the market. Patients using Nov
Read more(ShareCast News) - Investec resumed coverage on Vectura at 'buy' with a 200p price target following completion of the SkyePharma deal. "In our view, the benefits from a broader royalty base, improved cash flows, as well as an enhanced competency set, are yet to be fully reflected in the share price,
Read more(ShareCast News) - Inhaled airways disease focused company Vectura Group announced on Friday that a sales milestone receipt of $8m has been triggered following confirmation by Pacira Pharmaceuticals that worldwide annual net sales of EXPAREL, on a cash received basis to 30 June, were above $250m. Th
Read more* Digitally connected devices aim to track medicine use * GSK, AstraZeneca, Novartis all working on smart inhalers * Innovation drive comes as sector faces growing competition By Ben Hirschler LONDON, July 20 (Reuters) - Makers of inhalers to treat asthma and chronic lung
Read more(ShareCast News) - Skyepharma's chief financial officer Andrew Derodra has pocketed a healthy cash injection after the completion of the merger with Vectura. Derodra exercised nil-cost options over 150,000 Skyepharma shares that were a bonus in his long-term incentive plan that vested on completion
Read more